CD151/Integrin α6β1 Complex Specific Neutra™ Antibody Products

The CD151/Integrin α6β1 complex, involving CD151 of the tetraspanin family and Integrin α6β1, is crucial for cell-cell and cell-matrix interactions, affecting tissue integrity and cellular functions. It enhances functions in cell adhesion and migration, crucial in epithelial cell biology and stabilizing hemidesmosomes that connect cells to the basement membrane. This complex is significant in physiological processes like tissue repair and pathological conditions, including cancer metastasis, by promoting tumor cell invasiveness and supporting angiogenesis. It also plays roles in kidney diseases and skin disorders, making it a target for therapeutic development.

Signal Pathway of CD151/Integrin α6β1

The CD151/integrin α6β1 complex primarily affects cellular signaling by modulating the activity of kinases such as PI3K and MAPK, leading to changes in cell survival, proliferation, and motility. The binding of CD151 to integrin α6β1 can activate a series of signaling pathways, such as PI3K, Akt, NOS, JNK, JUN, and MMP-9, significantly influencing cell migration, invasion, and metastasis in cancer progression.

Study of CD151/Integrin α6β1 in Hepatocellular Carcinoma

In view of the fact that the four transmembrane protein CD151 plays multiple roles in the progression of hepatocellular carcinoma (HCC) by forming a functional complex with integrin α6β1, the researchers developed the monoclonal antibody 9B against CD151, which can dissociate the complex, and evaluated its biological activity in HCC. The monoclonal antibody targets the binding site between CD151 and Integrin α6β1, disrupting their interaction. This antibody has been shown to inhibit neoangiogenesis, tumor growth, and metastasis significantly. In vivo studies demonstrated that CD151 mAb 9B reduced tumor volume and weight, and notably decreased lung metastasis rates in treated xenograft models. These effects are attributed to the inhibition of the CD151-mediated pathways essential for HCC progression. This suggests that mAb 9B could serve as a promising therapeutic agent against hepatocellular carcinoma by targeting and modulating the CD151/Integrin α6β1 complex.

Fig. 1 The anti-CD151 antibody 9B against the CD151/integrin α6β1-binding site.¹

Creative Biolabs offers in-stock mouse-derived monoclonal antibodies that can specifically recognize the CD151/α6β1 complex. The purity and integrity of this product have been verified, helping our customers save time and expedite their experimental process.

REFERENCE

1. Ke, Ai-Wu, et al. "Generation and characterization of a tetraspanin CD151/integrin α6β1-binding domain competitively binding monoclonal antibody for inhibition of tumor progression in HCC." Oncotarget 7.5 (2016): 6314. Distributed under Open Access license CC BY 4.0, with modification. The image was modified by extracting and using only Part A of the original image.